Sesen Bio (SESN) Tops Q1 EPS by 40c

Sesen Bio (NASDAQ: SESN) reported Q1 EPS of $0.31, $0.40 better than the analyst estimate of ($0.09).

“In the first quarter of 2020, we successfully completed manufacturing of the pre-PPQ batch at Fujifilm,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. “We believe the commercial-scale cGMP batches of Vicinium manufactured to date at our CMOs are comparable to Vicinium previously manufactured by Sesen for use in our clinical trials. This reinforces our confidence in the upcoming PPQ campaign and our ability to demonstrate analytical comparability between clinical and commercial drug supply. The Company’s focus for 2020 remains the flawless execution of the PPQ campaign and the finalization of Module 3 to complete the Vicinium BLA submission.”

For earnings history and earnings-related data on Sesen Bio (SESN) click here.

You May Also Be Interested In

• Top AI Semiconductor Stocks According to Stifel Analysis
• HubSpot chief legal officer to resign in November
• RLI Corp. promotes four executives to expanded roles